{"d":{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')","uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')","type":"itsystems.Pd.DataServices.DataModel.Business"},"BusinessResponsibilities":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/BusinessResponsibilities"}},"RelatedBusinesses":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/RelatedBusinesses"}},"BusinessRoles":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/BusinessRoles"}},"Publications":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/Publications"}},"LegislativePeriods":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/LegislativePeriods"}},"Sessions":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/Sessions"}},"Preconsultations":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/Preconsultations"}},"Bills":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/Bills"}},"Councils":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/Councils"}},"BusinessTypes":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/BusinessTypes"}},"Votes":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/Votes"}},"SubjectsBusiness":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/SubjectsBusiness"}},"BusinessStates":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/BusinessStates"}},"Council":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/Council"}},"Transcripts":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Business(ID=20213166,Language='FR')/Transcripts"}},"ID":20213166,"Language":"FR","BusinessShortNumber":"21.3166","BusinessType":8,"BusinessTypeName":"Interpellation","BusinessTypeAbbreviation":"Ip.","Title":"Fiasco de l'achat de vaccin anti-Covid-19 (1). Rejet par n\u00e9gligence d'une offre pour 6 millions de doses de vaccin suppl\u00e9mentaires?","Description":null,"InitialSituation":null,"Proceedings":null,"DraftText":null,"SubmittedText":"<p>Selon la r\u00e9ponse que le Conseil f\u00e9d\u00e9ral a donn\u00e9e aux questions no 21.7365, 21.7366, 21.7367, 21.7368, 21.7369 et 21.7370 de l'heure des questions, les achats de vaccin ont \u00e9t\u00e9 discut\u00e9s et d\u00e9cid\u00e9s par l'ensemble du Conseil f\u00e9d\u00e9ral. Le d\u00e9lai serr\u00e9 l'ayant manifestement emp\u00each\u00e9 de r\u00e9pondre \u00e0 la question no 21.7365 pendant la session printemps, je le prie de le faire en vue de la session d'\u00e9t\u00e9 2021.</p><p>Le conseiller f\u00e9d\u00e9ral Alain Berset a d\u00e9clar\u00e9 le 8 mars 2021 devant le Conseil national qu'il ne pouvait \" ni confirmer ni commenter \" l'affirmation selon laquelle Pfizer-BioNTech a propos\u00e9 en d\u00e9cembre 2020 \u00e0 la Conf\u00e9d\u00e9ration d'acqu\u00e9rir 6 millions de doses de vaccin en plus des 3 millions de doses dont l'achat avait d\u00e9j\u00e0 \u00e9t\u00e9 convenu le 7 ao\u00fbt 2020. Pourquoi le Conseil f\u00e9d\u00e9ral a-t-il rejet\u00e9 cette offre de Pfizer-BioNTech, prolongeant ainsi le confinement au pr\u00e9judice de la Suisse\u00a0?</p>","ReasonText":null,"DocumentationText":null,"MotionText":null,"FederalCouncilResponseText":"<p>Le contrat sign\u00e9 avec Pfizer en d\u00e9cembre 2020 repose sur un accord pr\u00e9liminaire qui d\u00e9finit les points cl\u00e9s du contrat, tels que la quantit\u00e9 de doses de vaccins. Pfizer-BioNTech n'a pas propos\u00e9 en d\u00e9cembre 2020 \u00e0 la Conf\u00e9d\u00e9ration d'acqu\u00e9rir 6 millions de doses de vaccin suppl\u00e9mentaires. Ce n'est qu'apr\u00e8s avoir augment\u00e9 ses capacit\u00e9s de production d\u00e9but 2021 que Pfizer/BioNTech a propos\u00e9 des doses de vaccin suppl\u00e9mentaires \u00e0 la Conf\u00e9d\u00e9ration. Celle-ci a d\u00e9cid\u00e9 d'en commander le maximum, \u00e0 savoir 3 millions, qui sont arriv\u00e9es en Suisse \u00e0 partir d'avril 2021.</p>  R\u00e9ponse du Conseil f\u00e9d\u00e9ral.","FederalCouncilProposal":8,"FederalCouncilProposalText":null,"FederalCouncilProposalDate":"\/Date(1621987200000)\/","SubmittedBy":"Aeschi Thomas","BusinessStatus":229,"BusinessStatusText":"Liquid\u00e9","BusinessStatusDate":"\/Date(1679011200000)\/","ResponsibleDepartment":4,"ResponsibleDepartmentName":"D\u00e9partement de l'int\u00e9rieur","ResponsibleDepartmentAbbreviation":"DFI","IsLeadingDepartment":true,"Tags":"2841","Category":null,"Modified":"\/Date(1712764370043)\/","SubmissionDate":"\/Date(1615766400000)\/","SubmissionCouncil":1,"SubmissionCouncilName":"Conseil national","SubmissionCouncilAbbreviation":"CN","SubmissionSession":5108,"SubmissionLegislativePeriod":51,"FirstCouncil1":1,"FirstCouncil1Name":"Conseil national","FirstCouncil1Abbreviation":"CN","FirstCouncil2":null,"FirstCouncil2Name":null,"FirstCouncil2Abbreviation":null,"TagNames":"Sant\u00e9"}}